Aurobindo Pharma announces resignation of Dr. Sanjay Chaturvedi as CEO of subsidiary

Yash Agarwal — Mon, 04 May 2026 12:42:34 +0000

Aurobindo Pharma has announced the resignation of Dr. Sanjay Chaturvedi from his position as Chief Executive Officer of Apitoria Pharma Private Limited, a wholly owned subsidiary of the company. Dr. Chaturvedi has decided to pursue a different opportunity, and his resignation is effective from the close of business hours on 4 May 2026.

Dr. Chaturvedi’s departure marks a significant change in the leadership of Apitoria Pharma, which operates under the umbrella of Aurobindo Pharma. The company has not yet announced a successor for the CEO position at Apitoria Pharma.

Aurobindo Pharma is a prominent player in the pharmaceutical industry, known for its extensive range of generic medications and active pharmaceutical ingredients. The company continues to expand its global footprint and enhance its product offerings.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Aurobindo Pharma’s subsidiary facility classified as ‘Voluntary Action Indicated’ by US FDA

Business Desk — Fri, 20 Mar 2026 04:30:58 +0000

Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Apitoria Pharma Private Limited, has received a positive classification from the United States Food and Drug Administration (US FDA) for its Unit-V facility. The facility, located in Telangana, has been classified as ‘Voluntary Action Indicated’ (VAI) following an inspection.

The US FDA conducted an inspection of the Unit-V API manufacturing facility from December 1 to December 12, 2025. During this inspection, a ‘Form 483’ was issued with three observations. However, the subsequent Establishment Inspection Report (EIR) has now classified the facility as VAI, indicating that the inspection is closed and no further regulatory action is required.

This classification is significant for Aurobindo Pharma as it reflects the company’s commitment to maintaining high standards of manufacturing practices and compliance with US FDA regulations. The VAI status suggests that while there were observations noted during the inspection, they are not critical enough to warrant immediate regulatory action.

Aurobindo Pharma is a major player in the pharmaceutical industry, and this development is expected to bolster its reputation for quality and compliance in its manufacturing processes.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Apitoria Pharma | Business Upturn

Aurobindo Pharma announces resignation of Dr. Sanjay Chaturvedi as CEO of subsidiary

Aurobindo Pharma’s subsidiary facility classified as ‘Voluntary Action Indicated’ by US FDA